S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
Log in
NASDAQ:PSNL

Personalis Stock Forecast, Price & News

$26.22
-0.10 (-0.38 %)
(As of 10/29/2020 04:30 PM ET)
Add
Compare
Today's Range
$25.85
Now: $26.22
$27.13
50-Day Range
$20.02
MA: $24.47
$30.52
52-Week Range
$4.27
Now: $26.22
$30.95
Volume342,277 shs
Average Volume447,883 shs
Market Capitalization$836.02 million
P/E RatioN/A
Dividend YieldN/A
Beta1.87
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT platform, a clinical-grade, next generation sequencing and analysis platform that enables the development of ImmunoID NeXT tumor biopsy and liquid biopsy, as well as provides analysis of tumor and immune microenvironment from a single limited tissue sample, tumor molecular profiling for cancer patients, and anticipates future cancer biomarkers. The company also provides accuracy and content enhanced platform (ACE) that enhances nucleic acid preparation processes and combines it with patented assay and sequencing methods. ACE Platform offers multiple products and services, such as ACE extended cancer panel for DNA and RNA, and ACE cancer research Exome and Transcriptome. In addition, it develops NeXT Dx test, which helps oncologists to identify potential therapies and clinical trial options for cancer patients, as well as offers whole genome sequencing, which provides DNA sequencing and data analysis services; and ACE CancerPlus Test. The company also provides a liquid biopsy assay that analyzes various human genes versus the more narrowly focused liquid biopsy assays that are currently available. It serves approximately 50 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PSNL
CUSIPN/A
CIKN/A
Phone650-752-1300
Employees181

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$65.21 million
Book Value$3.42 per share

Profitability

Net Income$-25,080,000.00

Miscellaneous

Market Cap$836.02 million
Next Earnings Date11/5/2020 (Confirmed)
OptionableNot Optionable
$26.22
-0.10 (-0.38 %)
(As of 10/29/2020 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PSNL News and Ratings via Email

Sign-up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Personalis (NASDAQ:PSNL) Frequently Asked Questions

How has Personalis' stock price been impacted by COVID-19?

Personalis' stock was trading at $6.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PSNL stock has increased by 335.5% and is now trading at $26.22.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Personalis?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Personalis
.

When is Personalis' next earnings date?

Personalis is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Personalis
.

How can I listen to Personalis' earnings call?

Personalis will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Personalis' earnings last quarter?

Personalis (NASDAQ:PSNL) issued its quarterly earnings results on Thursday, August, 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.05. The company had revenue of $19.50 million for the quarter, compared to analysts' expectations of $17.05 million. Personalis had a negative return on equity of 31.11% and a negative net margin of 43.16%.
View Personalis' earnings history
.

What price target have analysts set for PSNL?

7 Wall Street analysts have issued 12 month price objectives for Personalis' shares. Their forecasts range from $24.00 to $35.00. On average, they anticipate Personalis' share price to reach $29.86 in the next twelve months. This suggests a possible upside of 13.9% from the stock's current price.
View analysts' price targets for Personalis
.

Are investors shorting Personalis?

Personalis saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 1,630,000 shares, an increase of 88.1% from the September 15th total of 866,400 shares. Based on an average daily volume of 599,100 shares, the days-to-cover ratio is presently 2.7 days. Approximately 7.2% of the shares of the stock are short sold.
View Personalis' Short Interest
.

Who are some of Personalis' key competitors?

What other stocks do shareholders of Personalis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Enphase Energy (ENPH), Pfizer (PFE), Dynavax Technologies (DVAX), QUALCOMM (QCOM), Advanced Micro Devices (AMD), NIO (NIO), NVIDIA (NVDA), Viking Therapeutics (VKTX), AbbVie (ABBV) and Aphria (APHA).

Who are Personalis' key executives?

Personalis' management team includes the following people:
  • Mr. John Stephen West, Co-Founder, CEO, Pres & Director (Age 63, Pay $785.44k)
  • Mr. Aaron L. Tachibana, Chief Financial Officer (Age 59, Pay $494.4k)
  • Dr. Richard Chen M.S., M.D., MS, Chief Scientific Officer (Age 49, Pay $543.75k)
  • Prof. Russ B. Altman, Co-Founder and Member of Clinical & Scientific Advisory Board
  • Mr. Euan A. Ashley, Co-Founder and Member of Clinical & Scientific Advisory Board

When did Personalis IPO?

(PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Personalis' stock symbol?

Personalis trades on the NASDAQ under the ticker symbol "PSNL."

Who are Personalis' major shareholders?

Personalis' stock is owned by many different retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (1.59%) and Cadence Capital Management LLC (0.04%). Company insiders that own Personalis stock include Aaron Tachibana, Ken Ludlum, Lightspeed Venture Partners Se, Llp Abingworth and Richard Chen.
View institutional ownership trends for Personalis
.

Which institutional investors are selling Personalis stock?

PSNL stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, and Candriam Luxembourg S.C.A.. Company insiders that have sold Personalis company stock in the last year include Aaron Tachibana, Ken Ludlum, Llp Abingworth, and Richard Chen.
View insider buying and selling activity for Personalis
.

How do I buy shares of Personalis?

Shares of PSNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Personalis' stock price today?

One share of PSNL stock can currently be purchased for approximately $26.22.

How big of a company is Personalis?

Personalis has a market capitalization of $836.02 million and generates $65.21 million in revenue each year. The company earns $-25,080,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Personalis employs 181 workers across the globe.

What is Personalis' official website?

The official website for Personalis is www.personalis.com.

How can I contact Personalis?

Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company can be reached via phone at 650-752-1300 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.